Search Results

Efaproxiral Sodium 50 mg  | 99.41%

TargetMol

Efaproxiral Sodium (RSR13 sodium), a synthetic allosteric modifier of hemoglobin, is utilized for brain metastases originating from breast cancer.

More Information Supplier Page

Hesperadin 10 mg  | 98.04%

TargetMol

Hesperadin(IC50=250 nM) effectively inhibits Aurora B. It potently reduces the activity of AMPK, MAPKAP-K1, MKK1, Lck, CHK1 and PHK, but it could not inhibit MKK1 activity in vivo.

More Information Supplier Page

Isepamicin sulfate 10 mg  | 98.58%

TargetMol

Isepamicin Sulphate, an aminoglycoside antibacterial with good activity against strains producing type I 6-acetyltransferase, inhibits bacterial protein synthesis by targeting the bacterial 30S ribosomal subunit.

More Information Supplier Page

Isepamicin sulfate 100 mg  | 98.58%

TargetMol

Isepamicin Sulphate, an aminoglycoside antibacterial with good activity against strains producing type I 6-acetyltransferase, inhibits bacterial protein synthesis by targeting the bacterial 30S ribosomal subunit.

More Information Supplier Page

IOX1 50 mg  | 99.38%

TargetMol

IOX1 is the most effective broad-spectrum 2OG oxygenases(including the JmjC demethylases) inhibitor. The IC50 of IOX1 for KDM4A, KDM3A, is 0.6 and 0.1 uM, respectively.

More Information Supplier Page

IOX1 10 mg  | 99.38%

TargetMol

IOX1 is the most effective broad-spectrum 2OG oxygenases(including the JmjC demethylases) inhibitor. The IC50 of IOX1 for KDM4A, KDM3A, is 0.6 and 0.1 uM, respectively.

More Information Supplier Page

Hesperadin 5 mg  | 98.04%

TargetMol

Hesperadin(IC50=250 nM) effectively inhibits Aurora B. It potently reduces the activity of AMPK, MAPKAP-K1, MKK1, Lck, CHK1 and PHK, but it could not inhibit MKK1 activity in vivo.

More Information Supplier Page

Hesperadin 50 mg  | 98.04%

TargetMol

Hesperadin(IC50=250 nM) effectively inhibits Aurora B. It potently reduces the activity of AMPK, MAPKAP-K1, MKK1, Lck, CHK1 and PHK, but it could not inhibit MKK1 activity in vivo.

More Information Supplier Page

PHA-665752 25 mg  | 99.35%

TargetMol

PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.

More Information Supplier Page

PHA-665752 10 mg  | 99.35%

TargetMol

PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.

More Information Supplier Page